Case Report: Clinical manifestations reported in a canine after ingesting ruxolitinib phosphate (Opzelura®)

TL;DR

A dog showed heart and eye issues after using a cream containing ruxolitinib phosphate, highlighting potential risks of JAK inhibitors in animals.

Contribution

This case report adds to the understanding of JAK inhibitor toxicosis in veterinary medicine through a specific canine case.

Findings

The dog developed cardiovascular and ocular abnormalities after ingesting ruxolitinib phosphate.

The case shows similarities in clinical manifestations to oclacitinib maleate overdoses in dogs.

The report emphasizes the need for awareness of JAK inhibitor toxicosis in veterinary practice.

Abstract

This case report describes a canine patient that developed cardiovascular and ocular abnormalities following ingestion of ruxolitinib phosphate 1.5% topical cream. The objective of this report is to characterize the exposure history, clinical presentation, diagnostic findings, therapeutic interventions, and to evaluate ruxolitinib phosphate within the context of its pharmacologic class, emphasizing similarities with related veterinary medications. Building on a recently published retrospective study of oclacitinib maleate overdoses, this case highlights shared clinical manifestations of ruxolitinib phosphate overdose and contributes to a broader understanding of JAK inhibitor toxicosis in veterinary medicine.